Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$83.23
pos +0.00
+0.00%
Today's Range: 79.50 - 83.81 | VRTX Avg Daily Volume: 2,331,000
Last Update: 02/12/16 - 4:00 PM EST
Volume: 0
YTD Performance: -33.86%
Open: $0.00
Previous Close: $79.71
52 Week Range: $78.51 - $143.45
Oustanding Shares: 245,717,286
Market Cap: 19,586,124,867
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 7 7 7
Moderate Buy 1 1 1 1
Hold 5 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.70 1.97 1.97 1.97
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -34.51
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-34.51 0.00 26.86
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-29.05% -24.08% 81.37%
GROWTH 12 Mo 3 Yr CAGR
Revenue -52.10 -0.32 -0.12
Net Income 0.00 10.54 0.00
EPS 0.00 3.62 0.00
Earnings for VRTX:
EBITDA -0.47B
Revenue 1.03B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.07 $0.27 $1.45 $4.67
Number of Analysts 2 2 2 1
High Estimate $0.16 $0.38 $1.85 $4.67
Low Estimate $-0.01 $0.15 $1.05 $4.67
Prior Year $-0.86 $-0.80 $-2.07 $1.45
Growth Rate (Year over Year) 108.72% 133.13% 170.05% 222.07%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishVertex upgraded at Jefferies

Feb 1, 2016 | 7:13 AM EST

VRTX was upgraded from Hold to Buy, Jefferies said. Valuation call, based on a $120 price target.

bullishVertex upgraded at HC Wainwright

Oct 30, 2015 | 7:26 AM EDT

VRTX was upgraded to Buy, HC Wainwright said. $155 price target. Company has a sound strategy and should continue to execute well. 

bullishVertex upgraded at Morgan Stanley

Oct 2, 2015 | 7:58 AM EDT

VRTX was upgraded from Equal-weight to Overweight, Morgan Stanley said. Company is transitioning toward profitability and should outperform. $148 price target. 

bullishVertex upgraded at Barclays

Sep 14, 2015 | 8:10 AM EDT

VRTX was upgraded to Overweight, Barclays said. $150 price target. Expert feedback suggest upside for Orkambi.

By

Jim Cramer

 | Aug 10, 2015 | 5:40 AM EDT

There are some good buying ideas among these stocks.

bearishVertex estimates, target cut at JMP

Jul 6, 2015 | 7:38 AM EDT

Shares of VRTX now seen reaching $145, according to JMP Securities. Estimates also reduced, given lower realized pricing for Orkambi. Outperform rating. 

By

Dan Fitzpatrick

 | May 27, 2015 | 5:00 PM EDT

Sector may not be as bulletproof as we thought.

By

Jim Cramer

 | May 13, 2015 | 11:17 AM EDT

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

bullishVertex estimates, target increased at Leerink

Apr 30, 2015 | 7:49 AM EDT

VRTX estimates were raised through 2016, Leerink Partners said. Orkambi should drive near-term growth. Outperform rating and new $150 price target. 

By

Jim Cramer

 | Apr 21, 2015 | 3:44 PM EDT

Biotech companies are saying, "I do."

Judge Smails embarrassed me into writing it!

Some pretty obvious selling in the FATMAN names vs the Nasdaq futures post regular session...
You can see the time/price support on the daily chart of SPX below. It also shows you the ...

$185.80
Exhausted and a long weekend.
Column up shortly
Sold some IWM as well.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.